13.3% Average Loss With Semaglutide in Obesity-Related HFpEF
A plain-English review of STEP-HFpEF, where semaglutide improved weight, symptoms, and walking distance in adults with obesity-related HFpEF.
Mean body-weight change was −13.3% with semaglutide and −2.6% with placebo; the KCCQ clinical summary score improved 7.8 points more with semaglutide.
529 adults with obesity-related heart failure with preserved ejection fraction and symptoms, without diabetes; 52 weeks. Read the linked peer-reviewed source for the full methodology, findings, and limitations.